An Effective COVID-19 Vaccine Needs to Engage T Cells | Semantic Scholar

Ending the current COVID-19 pandemic and preventing recurrence requires the development of vaccines that provide long-lasting immunity to the causative virus SARS-CoV-2 and its emerging variants where B cell epitopes can be mutated (1–3). We argue that to achieve this, a vaccine must elicit CD4 and CD8T cell immunity in addition to the production of neutralizing antibodies (nAB) by B cells. The rationale is based on the following findings for SARS-CoV-2 and the related SARS-CoV virus which caused the 2002/2003 SARS pandemic:

Sourced through from: